BioCentury | Apr 11, 2017
Clinical News

Tirabrutinib: Ph II started

...mg oral filgotinib ( GLPG0634 , GS-6034), 30 mg oral GS-9876 or 40 mg oral tirabrutinib...
...daily for up to 48 weeks in about 140 patients. Gilead has exclusive rights to tirabrutinib...
...Foster City, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Tirabrutinib ( GS-4059 , ONO-4059...
BioCentury | Apr 11, 2017
Clinical News

GS-9876: Ph II started

...filgotinib ( GLPG0634 , GS-6034), 30 mg GS-9876 or 40 mg tirabrutinib ( GS-4059 , ONO-4059...
...treat inflammatory diseases (see BioCentury, Dec. 21, 2015 ). Gilead also has exclusive rights to tirabrutinib...
BioCentury | Apr 11, 2017
Clinical News

Filgotinib: Ph II started

...200 mg filgotinib, 30 mg oral GS-9876 or 40 mg oral tirabrutinib ( GS-4059 , ONO-4059...
...tyrosine kinase (SYK) inhibitor, to treat rheumatoid arthritis (RA). Gilead also has exclusive rights to tirabrutinib...
BioCentury | Mar 16, 2015
Strategy

Bru-te force

...Co. Ltd. granted exclusive rights to Gilead outside of certain Asian countries to GS-4059 ( ONO-4059...
BioCentury | Dec 22, 2014
Company News

Ono Pharmaceutical, Gilead deal

...Ono granted Gilead exclusive rights to develop and commercialize ONO-4059 outside of Japan, South Korea, Taiwan...
...of Southeast Asian Nations (ASEAN) countries. The partners will jointly collaborate on global development of ONO-4059...
BioCentury | Dec 20, 2014
Company News

Gilead, Ono in Btk inhibitor deal

...Pharmaceutical Co. Ltd. (Tokyo:4528) granted Gilead Sciences Inc. (NASDAQ:GILD) exclusive rights to develop and commercialize ONO-4059...
BioCentury | Aug 28, 2014
Cover Story

Overcoming ibrutinib resistance

...Corp. (NASDAQ:CELG) CC-292 BTK B cell lymphoma; CLL Phase I Ono Pharmaceutical Co. Ltd. (Tokyo:4528) ONO-4059...
BioCentury | Jun 19, 2014
Distillery Therapeutics

Indication: Cancer

...to treat CLL and B cell lymphoma. Ono Pharmaceutical Co. Ltd. has the Btk inhibitor ONO-4059...
Items per page:
1 - 8 of 8